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Bloom’s syndrome (BS) displays one of the strongest known correlations between chromosomal instability and a high risk of
cancer at an early age. BS cells combine a reduced average fork velocity with constitutive endogenous replication stress. However,
the response of BS cells to replication stress induced by hydroxyurea (HU), which strongly slows the progression of replication
forks, remains unclear due to publication of conﬂicting results. Using two diﬀerent cellular models of BS, we showed that BLM
deﬁciencyisnotassociatedwithsensitivitytoHU,intermsofclonogenicsurvival,DSBgeneration,andSCEinduction.Wesuggest
that surviving BLM-deﬁcient cells are selected on the basis of their ability to deal with an endogenous replication stress induced
by replication fork slowing, resulting in insensitivity to HU-induced replication stress.
1.Introduction
Bloom’s syndrome (BS) combines marked genetic instability
with an increase in the risk of cancer development and
results from mutations in the BLM gene, which encodes
BLM, a RecQ 3 -5  DNA helicase [1]. BS cells have very high
frequencies of sister chromatid exchanges (SCEs) mediated
by RAD51-dependent homologous recombinations [2–4].
Physical and functional links between BLM, replication and
HR have been found. BLM deﬁciency is associated with
replication abnormalities [5–9] and with an increase in HR,
including a higher frequency of spontaneous symmetric
quadriradial interchanges, SCEs, and an increase in the
generation of homozygosity [10]. Following replication
arrest, BLM coprecipitates with RAD51 [11, 12] and the
primarymediatorsoftheS-phasecheckpoint,ATRandChk1
[13]. BLM and RAD51 are colocalized during replication
fork stalling and reside in a matrix-bound complex [14,
15]. During replication stress, BLM, 53BP1, and RAD51
form a complex; Chk1-mediated phosphorylation of 53BP1
enhances its binding to BLM and is required for the accumu-
lation of 53BP1 at the site of stalled replication, and BLM
enhances the colocalization of 53BP1 and RAD51 during
replication arrest [16]. BLM-deﬁcient cells display constitu-
tively large numbers of RAD51-containing foci. Both BLM
and 53BP1 abolish the formation of endogenous RAD51 foci
and disrupt RAD51 polymerization [11, 16]. SUMOylation
of BLM regulates its association with RAD51 by promoting
itsrecruitmentand/orretentiontodamagedreplicationforks
[17]. BLM also acts downstream from RAD51 to rescue
anaphase bridges resulting from RAD51 deﬁciency, probably
at diﬃcult-to-replicate DNA sequences such as fragile sites
[4]. In vitro, BLM unwinds DNA structures mimicking
replication forks and HR intermediates, such as D-loops,
and catalyzes the branch migration of Holliday junctions
[18–20]. It resolves double Holliday junctions, together
with topoisomerase IIIα, Rmi1/BLAP75, and Rmi2 [21, 22],
and catalyzes the regression of replication forks [23, 24].
BLM inhibits the D-loop formation catalyzed by RAD51,
by displacing RAD51 from single-stranded DNA, thereby
disrupting nucleoprotein ﬁlaments [25]. Several models of
the maintenance of genome integrity by BLM during DNA
replication have been developed, most suggesting that BLM
restarts replication after the stalling of the fork [26, 27]. In2 Journal of Nucleic Acids
theabsenceofBLM,cellsdisplayaslowingofreplicationfork
progression associated with constitutive replication stress
[9]. This raises questions about the response of BLM-
deﬁcient cells to an exogenous replicative stress slowing the
progression of replication still further, such as hydroxyurea
(HU). HU inhibits the ribonucleotide reductase commonly
used to induce replicational stress which slows fork rate
progression with respect to the temporal programme of
origin activation [28]. Conﬂicting data have been reported
concerning the sensitivity of BLM-deﬁcient cells to HU.
BLM-deﬁcient cells generated from the chicken DT40 B-
cell line display normal sensitivity to HU [29] whereas BS
lymphoblastoid cells are resistant to HU-induced apoptosis
[30], and BS GM08505 ﬁbroblast cells are hypersensitive to
HU [31]. In this paper, we used two diﬀerent cellular models
of BS to investigate the sensitivity of BLM-deﬁcient cells to
HU-inducedreplicationstress.WeshowthatBLMdeﬁciency
is not associated with sensitivity to HU, in terms of clonal
growth, DSB generation, and SCE induction. We discuss
these results in light of the reported cellular responses of
BLM-deﬁcient cells to replication stress.
2.MaterialsandMethods
2.1. Cell Cultures and Transfections. The SV40-transformed
BS ﬁbroblast cell line GM08505B and HeLa cells were used
as previously described [32]. HeLaV cells and HeLash cells
were obtained as described elsewhere [4]. For transient
transfection assay siRNAs, 3-4 × 105 c e l l sw e r eu s e dt os e e d
3ml of DMEM in six-well plates. Cells were transfected with
siRNAs speciﬁc for BLM (ON-TARGETplus, SMARTpool,
Dharmacon), or negative control siRNAs (ON-TARGETplus
siCONTROL Nontargeting Pool, Dharmacon) at a ﬁnal con-
centration of 100nM using DharmaFect 1TM (Dharmacon),
according to the manufacturer’s instructions.
BS-GFP and BS-GFP-BLM cells were obtained by trans-
fecting BS GM08505B cells with the EGFP-C1 vector alone
(Clontech, Mountain View, CA), or with this vector con-
taining the full length BLM cDNA [33], respectively, using
JetPEI reagent (Ozyme). After 48 hours, selection with 800
to 1600μg/ml of G418 (Invitrogen) was applied. Individual
colonies were isolated and maintained in DMEM containing
500μg/ml G418.
2.2. Chemicals. Hydroxyurea (HU) (Sigma) was used at a
ﬁnal concentration of 2mM or 5mM.
2.3. Western Blot Analysis. Cells were lysed in 350mM
NaCl, 50mM Tris-HCl pH 7.5, 1% NP-40, 1mM NaF, and
protease inhibitors for 30min on ice, sonicated and heated.
S a m p l e se q u i v a l e n tt o1 5o r3 0μg of protein were subjected
to electrophoresis in Novex 4–12% Bis-Tris precast gels
(Invitrogen).Theproceduresusedforgelelectrophoresisand
immunoblotting were as previously described [34].
2.4. Flow Cytometry Analysis. C e l l sw e r eﬁ x e dw i t h7 0 %
ethanol at −20
◦C for at least 30min. After 2 washes,
cells were incubated for 30min at 37
◦C in PBS containing
100μg /ml RNase A (Sigma) and 10μg/m1 propidium iodide
(Sigma). The DNA content was determined by measur-
ing ﬂuorescent intensities on FACS-calibur ﬂow cytometer
(Becton Dickinson). Data were processed with Cell Quest
software.
2.5. Antibodies. All the commercial antibodies were used
according to the manufacturers’ speciﬁcations. The primary
antibodies used against BLM were ab476 (1:1000; rabbit,
Abcam) and C18 (1:150; goat, Santa-Cruz Biotechnology).
We used rabbit polyclonal antibodies against Chk1 ser317,
Chk2 threonine 68, and H2AX serine 139 (1:1000; Cell
Signaling), β-actin (1:10000; Sigma), and GAPDH (1:5000;
Millipore).
Horseradish peroxidase-conjugated goat antimouse IgG
and goat antirabbit IgG (Santa Cruz Biotechnology) were
used as secondary antobodies, at dilutions of 1:5000 and
1:10000.
2.6. Sister Chromatid Exchange Assays. Cells were left
untreated or were transfected as indicated. After 24h of
transfection with siRNA, cells were left untreated or were
treated with HU, transferred to slides and cultured in the
presence of 10mM 5-bromodeoxyuridine (Sigma) at 37
◦C,
under an atmosphere containing 5%CO2.A f t e r4 0h( H e L a V
and HeLashBLM cells) or 50h (BS-GFP or BS-GFP-BLM)
of incubation, colchicine (Sigma) was added to a ﬁnal
concentration of 0.1mg/ml, and the cells were incubated for
1hour.Theywerethenincubatedinhypotonicsolution(1:6
(vol/vol) FCS-distilled water) and ﬁxed by incubation with a
3:1 (vol/vol) mixture ofmethanol andacetic acid. Cells were
then stained by incubation with 10mg/ml Hoechst 33258
(Sigma) in distilled water for 20 minutes, rinsed with 2 ×
SSC (Euromedex), exposed to UV light at 365nm and at a
distance of 10cm for 105 minutes, rinsed in distilled water,
stained by incubation with 2% Giemsa solution (VWR) for
16 minutes, rinsed in distilled water, dried, and mounted.
Chromosomes were observed with a Leica DMRB micro-
scope at 100x magniﬁcation. Metaphases were captured with
a SONY DXC 930 P camera, and SCEs were analyzed.
2.7. Clonogenic Survival Assays. Untreated or HU-treated
cells were plated in drug-free medium at 3 densities, in
triplicate, for the counting of 30 to 300 clones depending
on expected survival. Alternatively, cells were plated and
treated as previously described [31]. After 14 to 21 days of
incubation colonies were ﬁxed and stained with methylene
blue (5g/l in 50% water and 50% methanol) and scored.
Only experiments giving a linear correlation between the
diﬀerent dilutions were considered. Cell survival was esti-
mated by dividing the number of colony-forming units in
treated samples by the number of colony-forming units in
untreatedsamples,withcontrolcellsurvivaldeﬁnedas1.The
percentageofcellsurvivalisindicatedwithineachhistogram.
2.8. Comet Assays. BS-GFP and BS-GFP-BLM cells or
HeLashBLM and HeLaV transfected as in Figure 1(a) were
leftuntreatedorweretreatedwith2mMHUfor16hor48h.Journal of Nucleic Acids 3
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Figure 1: BLM-downregulated HeLa cells and BS cells are insensitive to HU-induced replication stress. (a) HeLaV and HeLashBLM cells
were transfected with 100nM of a negative control siRNA (ctrl) or with 100nM of siRNA targeting the BLM mRNA (BLM), respectively.
After 24h, cells were left untreated or were treated with 2mM or 5mM HU for 16h. Cells were then plated in triplicate at three densities in
drug-free medium. The means of six independent experiments for 2mM HU and of two independent experiments for 5mM HU are shown.
The error bars indicate SD. (b) As in (a) except that cells were treated with 2mM HU for 48hr, the means of 3 independent experiments are
shown. (c) BS-GFP and BS-GFP-BLM cell lines were left untreated or were treated with 2mM HU for 16h and plated as in (a). The means
of 3 independent experiments are shown.
After24h,cellswereleftuntreatedorweretreatedwith2mM
HU for 16h or 48h. At the end of the treatment period,
the cells were treated with Accutase (PAA). Aliquots of cell
suspension were mixed with an equal volume of 1% low-
melting-point agarose in DMEM to obtain a suspension of
cells in 0.5% agarose, which was then dispensed onto micro-
scope slides (with frosted ends) coated with a layer of 0.5%
normal-melting-point agarose. Slides were incubated in lysis
solution [2.5mol/L NaCl, 100mmol/L EDTA, 10mmol/L
Tris, 1% sodium lauryl sarcosinate, 10% DMSO, and 1%
TritonX-100 (pH 10)] at 4◦C for 1h, then denaturated in
alkali buﬀer (0.3mol/L NaOH, pH 13 and 1mmol/L EDTA)
for 40 minutes at 20
◦Ca n ds u b j e c t e dt oe l e c t r o p h o r e s i s
for 25min at 25V (300mA). Slides were immersed in
neutralization buﬀer (400mmol/L Tris-HCl, pH 7.5) for at
least5minutes.Theywerethendrained,rinsedcarefullywith
distilled water, and stained with ethidium bromide staining
solution (20μg/ml) before being covered with a coverslip.
For the visualization of DNA damage, ethidium bromide-
stained DNA was observed at a magniﬁcation of x20, under
a ﬂuorescence microscope. Between 100 and 110 cells per
sample and per experiment were analyzed in Comet Assay
2 software (Perceptive Instrument).
2.9. Statistical Methods. Signiﬁcance was assessed with Stu-
dent’s t-test. For all tests, P<. 05 was considered statistically
signiﬁcant.
3. Results
3.1. Both HeLa Cells with BLM Downregulation and BS
Cells Are Insensitive to HU-Induced Replication Stress. We
investigated whether BLM downregulation was associated
with changes in the sensitivity of cells to HU-induced
replication stress. We ﬁrst used a new cellular model for BS
consisting of HeLa cells constitutively expressing an shRNA
speciﬁc for BLM and transiently transfected with a pool of
siRNAs directed against sequences other than that targeted4 Journal of Nucleic Acids
byshBLM(HeLash-siBLM),togetherwiththecorresponding
control cells (HeLaV-sictrl) [4]. We assessed HeLash-siBLM
sensitivity to HU in clonogenic survival assays. BLM mRNA
levels and SCE frequency were assessed in all experiments
with HeLash-siBLM (data not shown). After treatment with
2 or 5mM HU for 16hr, HeLash-siBLM cells were either
less sensitive or displayed similar levels of sensitivity to
HU than control cells, respectively (Figure 1(a)). As BS cell
hypersensitivity was reported after 48h of exposure to HU
concentrations from 0.01 to 10mM in a previous study
[31], we repeated the experiments after 48h of exposure
to 2mM HU. The clonogenic survival of both HeLa cells
with BLM downregulation and control cells was strongly
decreased, with BLM-downregulated cells signiﬁcantly more
sensitive to 48h of exposure to HU than control cells
(Figure 1(b)). These experiments were repeated with BS
GM08505 ﬁbroblasts (BS-GFP) and their complemented
counterparts(BS-GFP-BLM)(seeSection 2).Theclonogenic
survival of BS cells and control cells was similar after 16h
of exposure to HU (Figure 1(c)). After 48h of exposure to
HU, we detected no clones, for either BS cells or BLM-
complemented cells. Increasing the number of cells plated by
afactor10andusingtwodiﬀerentprotocolsdidnotaﬀectthe
results obtained. This indicates that the BS cell line we used
behaves diﬀerently from the one used by Davies et al. [31],
potentially because one of them derived in culture due to the
mutator and hyper-rec phenotype of BS cells [1]. Altogether
our results indicate that in terms of clonal survival, BLM
deﬁciency is not associated with an increase in the sensitivity
to16hoftreatmentwithHU.However,BLM-downregulated
HeLa cells are signiﬁcantly more sensitive to 48h of HU
treatment than control cells are.
3.2. Levels of HU-Induced DSBs Are Similar in BLM-Deﬁcient
Cells and in Control Cells. The prolonged treatment of
cells with HU results in the accumulation of DSBs [35].
We carried out a time-course study of the eﬀect of HU
on DSB levels in BLM-downregulated HeLa cells and in
control cells. DSB induction was assessed by evaluating levels
of histone H2AX phosphorylated at serine 139 (γ-H2AX)
and of checkpoint kinase 2 phosphorylated at threonine
68 (Chk2 pT68). Chk1 activation and BLM accumulation
were induced by blocking replication [34, 36]. We therefore
determined the levels of activated Chk1 phosphorylated
at serine 345 (Chk1 pS345) and BLM. The progressive
accumulation of BLM in control cells was observed, with
the highest levels after 16 to 24h of exposure to HU
(Figure 2(a)). No BLM was detected in HeLash-siBLM cells,
as expected. The eﬃciency of replication blockade by HU
was conﬁrmed by FACS analysis and by the detection of
activated Chk1 in both control cells and BLM-depleted HeLa
cells. Signiﬁcantly higher levels of accumulation of γ-H2AX
and activated Chk2 were observed in control cells and in
BLM-downregulated HeLa cells after 48h of HU exposure
than after 16h (Figure 2(a)). The amounts of γ-H2AX and
of Chk2pT68 detected in response to HU treatment were
similar in BLM-deﬁcient cells and in control cells. In BS-
GFP cells and their complemented counterparts, γ-H2AX
accumulation was also stronger after 48h of HU treatment
than after 16h (Figure 2(b)).
We evaluated HU genotoxicity in BLM-deﬁcient cells
further, by carrying out an in vitro alkaline DNA comet
assay [37]. The mean tail moment (a numerical mea-
surement of the DNA damage deﬁned as the product of
the tail length and the fraction of total DNA in the tail)
was similar in BLM-deﬁcient cells (HeLash-siBLM or BS-
GFP) and in control cells (HeLaV-sictrl or BS-GFP-BLM,
respectively), whether untreated or treated with 2mM HU
for 16h (Figures 2(c), 2(d),a n d2(e)). However, the mean
tail moment was signiﬁcantly higher after 48h of HU
treatment than in the absence of treatment or after 16h
of treatment, by a factor of about two in both BS cells
and their complemented counterparts (Figure 2(e)), and by
factors of four to ten in BLM-downregulated HeLa cells
and their controls (Figure 2(d)). Thus, 16h of treatment
with 2mM HU activates the Chk1-mediated replication
checkpoint but does not generate a signiﬁcant increase in
DNAdamagewhereas48hoftreatmentwith2mMHUleads
to a signiﬁcant increase in DNA damage, to similar levels
in BLM-deﬁcient cells control cells. BLM deﬁciency is not
therefore associated with an increase in DSB induction in
response to HU.
3.3. HU Treatment Induces a Similar Increase in the Fre-
quency of SCEs in BLM-Deﬁcient Cells and Control Cells.
HU treatment eﬃciently induces SCEs formation [38]. We
analyzed the eﬀect of HU-induced replication stress on SCEs
levels in BLM-deﬁcient cells and in control cells. We found
a slight but signiﬁcant increase in SCE levels in both BLM-
downregulated HeLa cells (x1.4) and in BS cells (x1.3) this
increase is similar to that observed in the corresponding
control cells (x1.7 and x1.4, resp.) (Figures 3(a) and 3(b)).
Thus, BLM deﬁciency is not associated with an increase in
SCEs induction in response to HU.
4. Discussion
Weusedhydroxyureatoinvestigatethecellularconsequences
of HU-induced replication stress in two cellular models of
BS.WefoundthatalthoughBLM-deﬁcientcellshaveastrong
increase in SCE frequency due to BLM deﬁciency, the further
increase in the SCE frequency induced by the treatment
with HU was similar to that of control cells. Thus, BLM
deﬁciency is not associated with sensitivity to HU in terms
of SCE induction. We also showed that BLM-deﬁcient cells
were insensitive to HU induced replication stress (2 or 5mM
HU for 16h), consistent with the normal sensitivity to HU
of the BLM-defective chicken DT40 cells [29]. By contrast,
Davies et al. [31] showed that BS cells were hypersensitive
to prolonged exposure to HU. We also found that BLM-
downregulated HeLa cells were signiﬁcantly more sensitive
to treatment with HU for 48h than control cells were. We
investigated the reasons for this sensitivity of BLM-deﬁcient
cells to 48h of HU treatment but not to 16h of treatment, by
analyzingtheeﬀectsofHUonDSBinduction.Wefoundthat
48h of HU treatment generated numerous DSBs whereasJournal of Nucleic Acids 5
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Figure 2: Levels of HU-induced DSBs are similar in BLM-deﬁcient cells and control cells. (a) HeLaV and HeLashBLM cells were transfected
as in Figure 1(a). Upper panel: After 24 h, cells were left untreated (0) or were treated with 2mM HU for the indicated times. Protein
extracts were subjected to SDS-PAGE. The membrane was probed with anti-BLM (C18), anti-Chk1 pS345, anti-Chk2 pT68, and anti-γ-
H2AX antibodies, and with anti-β-actin antibody, as a loading control. The membrane was stripped and reblocked between successive
antibody incubations. Lower panel: After 24h, cells left untreated or treated with 2mM HU for 16h were harvested, ﬁxed, and analyzed by
FACS. (b) BS-GFP and BS-GFP-BLM cells were left untreated or were treated with 2mM HU for the indicated times. Protein extracts were
subjected to SDS-PAGE and the bands were transferred to a membrane. The membrane was probed with anti-BLM (C18), anti-γ-H2AX
antibodies, and with anti-GAPDH antibody, as a loading control. Lower panel: After 24h, cells left untreated or treated with 2mM HU
for 16h were harvested, ﬁxed, and analyzed by FACS. (c) Representative images of HeLa cells in the comet assays. (Left) Untreated cell.
(Right) Example of cell displaying an increase in DNA migration after 48h of HU treatment, due to DNA breaks. (d) The eﬀe c to f2m M
HU treatment on DNA migration (tail moment) in the comet assays with HeLaV and HeLash BLM cells transfected as in Figure 1(a).A f t e r
24h of transfection, cells were left untreated or were treated with 2mM HU for 16h or 48h. The cells were subjected to comet assays (see
Section 2). Two independent experiments were analyzed for each set of conditions. Between 100, and 110 cells were scored for each set of
conditions, in each experiment. Error bars represent standard errors of the mean. (e) As in (d), using BS-GFP-BLM or BS-GFP cells left
untreated or treated with 2mM HU for 16h or 48h.6 Journal of Nucleic Acids
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Figure 3: Levels of HU-induced SCEs are similar in BLM-deﬁcient
cells and control cells. (a) Number of SCEs per chromosome in
HeLaV or in HeLashBLM cells transfected as in Figure 1(a),l e f t
untreated or treated with 2mM HU for 16h. Between 2174 and
4314 chromosomes from 5 independent experiments were analyzed
for each set of conditions. Errors bars represent standard errors
of the means. (b) Number of SCEs per chromosome in BS-GFP-
BLM and BS-GFP cells left untreated or treated as in (a). Between
1864and2255chromosomesfrom4independentexperimentswere
analyzed for each set of conditions. Errors bars represent standard
errors of the means.
16h of treatment did not, as expected [35]. However, the
DSB levels determined on the basis of γ-H2AX detection or
in comet assays were found to be similar in BLM-deﬁcient
cells and in control cells treated with HU, indicating a lack of
association between BLM deﬁciency and an increase in DSB
induction by HU. These results are consistent with the data
reported by Rao et al. [39] showing that despite the delay
in H2AX phosphorylation on serine 139 observed in BLM-
deﬁcient cells treated with HU (1mM) or camptothecin
(1μM), the number of γ-H2AX foci per nucleus reaches
that of control cells 6h after either of these treatments.
Camptothecin inducesreplication-associatedDSBs[40],and
BS cells are hypersensitive to camptothecin [39]. These
results indicate that the reported diﬀerences in the sensitivity
of BLM-deﬁcient cells to HU reﬂect diﬀerences in their
sensitivity to HU-induced DSBs; this sensitivity depends on
the numbers of DSBs generated by the HU treatment, but
not on HU-induced replication stress per se that is associated
withfewDNAbreaks.Indeed,unstressedBLM-deﬁcientcells
have DNA replication defects, resulting in spontaneously
arrested replication forks and a decrease in the distance
between origins [8, 9]. Such inhibition of the progress
of replication forks may render BS cells susceptible to
some DNA breaks, accounting for constitutive endogenous
ATM-Chk2-γH2AX checkpoint activation detected only by
immunoﬂuorescence [9]. Such checkpoint activation has
been found in clinical specimens from human tumours at
various stages and in cultured cells subjected to replication
stress [41, 42]. Endogenous ATM-Chk2-γH2AX activation
in BS cells is thus thought to reﬂect a precancerous state,
with replication stress associated with few DNA breaks [9].
If BS cells were hypersensitive to such replication stress,
they would not survive this constitutive replication defect.
We therefore suggest that surviving BLM-deﬁcient cells have
been selected on the basis of their ability to survive in the
presence of a constitutive replication stress associated with
few DNA breaks.
5. Conclusion
We showed that the clonogenic survival of BLM-deﬁcient
cells was insensitive to hydroxyurea (HU)-induced repli-
cation stress. Gamma-H2AX detection and comet assays
revealed the numbers of DNA double-strand breaks (DSB)
generated by HU treatment to be similar in BLM-deﬁcient
cellsandcontrolcells.Moreover,BLMdeﬁciencydidnotfur-
ther increase the frequency of HU-induced sister chromatid
exchanges (SCEs). We propose that BLM-deﬁcient cells are
selected to survive with an endogenous replication stress
induced by replication fork slowing, resulting in insensitivity
to HU-induced replication stress.
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